Mirum (MIRM) president sells 16,515 shares, exercises 30,220 RSUs
Rhea-AI Filing Summary
Mirum Pharmaceuticals president and COO Peter Radovich reported a combination of equity award vesting and share sales. He exercised performance restricted stock units into 30,220 shares of common stock at a conversion price of $0.00 per share, increasing his direct holdings.
On the following day, he sold 16,515 common shares at an average price of $91.9779 per share, with a footnote stating the sale was to cover tax withholding obligations from the RSU vesting. After these transactions, he directly holds 40,272 common shares and continues to hold 11,500 performance restricted stock units scheduled to vest over future dates.
Positive
- None.
Negative
- None.
Insights
Routine equity award vesting with tax-related share sale, minimal signal.
Peter Radovich, president and COO of Mirum Pharmaceuticals, exercised performance restricted stock units into 30,220 common shares at a conversion price of $0.00. This reflects standard equity compensation vesting rather than an open-market purchase.
He then sold 16,515 shares of common stock at $91.9779 per share on March 16, 2026. A footnote states these shares were sold to satisfy tax withholding obligations tied to the RSU vesting, a mechanistic transaction with weak informational value about his view of the stock.
Following these moves, Radovich directly owns 40,272 common shares and retains 11,500 performance restricted stock units that vest in tranches on March 15, 2026 and March 15, 2027. Overall, this filing shows routine compensation events rather than a thesis-changing insider trade.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 16,515 | $91.9779 | $1.52M |
| Exercise | Performance Restricted Stock Units | 7,220 | $0.00 | -- |
| Exercise | Performance Restricted Stock Units | 23,000 | $0.00 | -- |
| Exercise | Common Stock | 7,220 | $0.00 | -- |
| Exercise | Common Stock | 23,000 | $0.00 | -- |
Footnotes (1)
- Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units. The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026. The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.